PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in
Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the
primary endpoint evaluation at Week 14. During the open label extension, subjects who
received NAL ER will continue on NAL ER and subjects who received placebo will crossover to
NAL ER.